Know Cancer

forgot password

A Phase II Open Label Single-Arm Study of E7389 in Patients With Locally Advanced or Metastatic Breast Cancer, Previously Treated With Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease

Phase 2
18 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

A Phase II Open Label Single-Arm Study of E7389 in Patients With Locally Advanced or Metastatic Breast Cancer, Previously Treated With Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease

Inclusion Criteria:

1. Female patients with histologically or cytologically confirmed carcinoma of the
breast. Every effort should be made to make paraffin embedded tissue or slides from
the diagnostic biopsy or surgical specimen available for confirmation of diagnosis.

2. Patients with locally advanced or metastatic disease who have received at least two
(and not more than five) prior chemotherapeutic regimens for breast cancer, at least
one of which was administered for treatment of locally advanced or metastatic

Prior therapy must be documented by the following criteria prior to entry onto study:

- Regimens must have included an anthracycline (eg, doxorubicin, epirubicin), a
taxane (eg, paclitaxel, docetaxel) and capecitabine in any combination or order.

- One or two of these regimens may have been administered as adjuvant and/or
neoadjuvant therapy.

- Patients with human epidermal growth factor receptor 2 (HER2/neu)
over-expressing tumors must additionally have been treated with trastuzumab.

- Patients with estrogen receptor-expressing tumors may have additionally been
treated with estrogen-specific therapy.

- Prior hormonal therapy, biological therapy, (eg, trastuzumab, bevacizumab), or
immunotherapy, is not to be counted as one of the 2 to 5 prior chemotherapy
regimens allowed. However, hormonal therapy must be discontinued one week before
administration of E7389, and biological therapy must be discontinued two weeks
before E7389 administration.

- Patients who are being treated with bisphosphonates when they enter the study
are allowed to continue the medication as long as the dosing does not change. In
case a change in dosing is deemed necessary, the case needs to be discussed with
the Sponsor.

3. Progression on or within six months of the last regimen for advanced disease,
documented by the following:

- The dates of treatment, doses, outcome of therapy and the reason for
discontinuation of prior anthracycline, taxane, capecitabine, and trastuzumab
therapy must be provided.

- Prior to entry onto the study, information ensuring that the last therapy
fulfills eligibility criteria is required, which includes progression while
receiving this last prior chemotherapy regimen, or within six months of
receiving that therapy.

- Chemotherapy medication administration sheets or other official medical/hospital
records indicating type and dates of chemotherapy must be available for
inspection, and one of the following as a reason for discontinuation of
medication is required: radiographic evidence of progression, or doctor's office
or hospitalization notes documenting radiologic progression, clinically
documented increase in tumor burden, and/or increase in tumor-specific markers.

4. Patients with measurable disease by Response Evaluation Criteria in Solid Tumors
(RECIST) criteria, defined as at least one lesion that can be accurately measured in
at least one diameter (at least 10 mm in longest diameter [LD] by spiral computer
tomography [CT] scan), or at least 20 mm by standard techniques. If the only
measurable lesion is a lymph node, it must measure at least 20 mm in LD. If a single
lesion is identified as the target lesion, a biopsy or aspiration with cytological or
histological confirmation of the diagnosis of breast carcinoma is required.

5. Resolution of all chemotherapy or radiation-related toxicities to less than Grade 2
severity, except for stable sensory neuropathy ≤ Grade 2 and alopecia.

6. Age >= 18 years.

7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.

8. Life expectancy of ≥ 3 months.

9. Adequate renal function as evidenced by serum creatinine ≤ 2.0 mg/dL or calculated
creatinine clearance ≥ 40 mL/minute (min) per the Cockcroft and Gault formula.

10. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) ≥1.5 x
10^9/L hemoglobin ≥ 10.0 g/dL (acceptable if it is corrected by therapeutic
intervention or transfusional support), and platelet count ≥ 100 x 10^9/L.

11. Adequate liver function as evidenced by bilirubin ≤ 1.5 mg/dL and alkaline
phosphatase, alanine transaminase (ALT), and aspartate transaminase (AST) ≤ 3 times
the upper limits of normal (ULN) (in the case of liver metastases ≤ 5 x ULN), unless
there are bone metastases, in which case liver specific alkaline phosphatase must be
separated from the total and used to assess the liver function instead of the total
alkaline phosphatase.

12. Willing and able to complete the European Organization for Research on the Treatment
of Cancer (EORTC) quality of life assessment, Analgesic Diary, and Pain Visual Analog
Scale (VAS).

13. Willing and able to comply with the study protocol for the duration of the study.

14. Written informed consent prior to any study-specific screening procedures with the
understanding that the patient may withdraw consent at any time without prejudice.

Exclusion Criteria:

1. Patients must not have received chemotherapy, radiation, or biologic therapy within
two weeks, hormonal therapy within one week, or trastuzumab within three weeks,
before E7389 treatment start.

2. Patients must not have received radiation therapy encompassing > 30% of marrow (a
lesion that has been irradiated cannot be used as a target lesion, unless it has
progressed after the irradiation).

3. Patients must not have pre-existing neuropathy > Grade 2.

4. Patients must not have participated in a prior E7389 clinical trial.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective Response Rate

Outcome Description:

Based on Response Evaluation Criteria in Solid Tumors (RECIST), consisting of complete response (CR) plus partial response (PR). Defined as the best response from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions).

Outcome Time Frame:

Every two cycles

Safety Issue:


Principal Investigator

Dale Shuster, Ph.D.

Investigator Role:

Study Director

Investigator Affiliation:

Eisai Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

October 2005

Completion Date:

September 2007

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms



Harrington Cancer Center Amarillo, Texas  79106
Yakima Valley Memorial Hospital Yakima, Washington  98902
University of Kansas Medical Center Kansas City, Kansas  66160-7353
Comprehensive Cancer Centers of Nevada Las Vegas, Nevada  89109
Rocky Mountain Cancer Center Denver, Colorado  80218
Wilshire Oncology Medical Group, Inc. Rancho Cucamonga, California  91730
Missouri Cancer Associates Columbia, Missouri  65201
Tyler Cancer Center Tyler, Texas  75702
Cancer Care Northwest Spokane, Washington  99202
Cancer Care Associates Tulsa, Oklahoma  74136
Willamette Valley Cancer Center Eugene, Oregon  97401-8122
SUNY Upstate Medical University Syracuse, New York  13210
Arkansas Cancer Research Center Little Rock, Arkansas  72205
University of Chicago Chicago, Illinois  60637
Charleston Hematology Oncology Charleston, South Carolina  29403
North Texas Regional Cancer Center Plano, Texas  75075
Rocky Mountain Cancer Center-Midtown Denver, Colorado  80218
Utah Cancer Specialists Salt Lake City, Utah  84106
Decatur Memorial Hospital Decatur, Illinois  62526
Montana Cancer Specialists Missoula, Montana  59807-7877
Northern Indiana Cancer Research Consortium South Bend, Indiana  
North Shore Hematology Oncology Associates East Setauket, New York  11733
Birmingham Hematology and Oncology Birmingham, Alabama  35235
El Paso Cancer Treatment Center El Paso, Texas  79915
Central indiana Cancer Center Indianapolis, Indiana  46227
Raleigh Hematology Oncology Associates Cary, North Carolina  27511
Center for Oncology Research and Treatment, PA Dallas, Texas  75230
Hematology-Oncology Associates Pensacola, Florida  32501
Park Nicollet Institute St Louis Park, Minnesota  55416
University of Tennessee Medical Center Knoxville, Tennessee  37920
Mercy Cancer Center Hot Springs, Arkansas  71913
Rocky Mountain Cancer Center-Rose Denver, Colorado  80220
Cancer Research Network Plantation, Florida  33324
Dr. Elizabeth Tan-Chiu, PA Tamarac, Florida  33321
Peachtree Hematology And Oncology Consultants Atlanta, Georgia  30309
Cancer Care and Hematology Specialist of Chicagoland Niles, Illinois  60714
Monroe Medical Center Munster, Indiana  46321
Frederick Memorial Hospital, Regional Cancer Therapy Center Frederick, Maryland  21701
New York Oncology Hematology, P.C Albany, New York  12208
Huntington Medical Group, PC Huntington Station, New York  11746
Weill Cornell Breast Cancer Center New York, New York  10021
Northwestern Carolina Oncology And Hematology, PA Hudson, North Carolina  28602
'Signal Point Hematology/Oncology, Inc. Middletown, Ohio  45042
Medical University of Ohio Toledo, Ohio  43614
Kaiser Permanente, Central Interstate Clinic, Hematology Oncology Portland, Oregon  97227
Northwest Cancer Specialist Hoyt Portland, Oregon  97227
Northwest Cancer Specialist Rose Qtr Portland, Oregon  97225
Texas Oncology, P.A. Bedford Bedford, Texas  76022
Sammons Cancer Center-Dallas Dallas, Texas  75246
Texas Oncology PA Dallas, Texas  75231
El Paso Cancer Treatment Center West El Paso, Texas  79902
Baylor College of Medicine, Breast Cancer Clinic Houston, Texas  77030
Valley Oncology PA Weslaco, Texas  78596
Fairfax Northern VA Hematology Oncology PC Fairfax, Virginia  22031
Oncology and Hematology Associates Salem, Virginia  24153
Northwest Cancer Specialist Vancouver, Washington  98684